ARIANNA SAVI

Dr. ARIANNA SAVI

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
GPGiovangiacinto Paterno
Giovangiacinto Paterno
RPRaffaele Palmieri
Raffaele Palmieri
VFVittorio Forte
Vittorio Forte
VPValentina Del Prete
Valentina Del Prete
CGCarmelo Gurnari
Carmelo Gurnari
MPMaria Ilaria Del Principe
Maria Ilaria Del Principe
Information regarding the incidence and the prognostic impact of thrombotic events (TE) in non-promyelocytic acute myeloid leukemia (AML) is sparse. Although several risk factors associated with an increased risk of TE development have been recognized, we still lack universally approved guidelines for identification and management of these complications. We retrospectively analyzed 300 consecutive patients with newly diagnosed AML. Reporting the incidence of venous TE (VTE) and arterial TE (ATE) was the primary endpoint. Secondarily, we evaluated baseline patient- and disease-related characteristics with a possible influence of VTE-occurrence probability. Finally, we evaluated the impact of TE on survival. Overall, the VTE incidence was 12.3% and ATE incidence was 2.3%. We identified three independent predictors associated with early-VTE: comorbidities (p = 0.006), platelets count >50 × 109/L (p = 0.006), and a previous history of VTE (p = 0.003). Assigning 1 point to each variable, we observed an overall cumulative incidence of VTE of 18.4% in the high-risk group (≥2 points) versus 6.4% in the low-risk group (0–1 point), log-rank = 0.002. Overall, ATE, but not VTE, was associated with poor prognosis (p < 0.001). In conclusion, TE incidence in AML patients is not negligible. We proposed an early-VTE risk score that could be useful for a proper management of VTE prophylaxis.

Verified
Journal Article
Open access
PDF file
EMElisa Meddi
Elisa Meddi
ASARIANNA SAVI
ARIANNA SAVI
FMFederico Moretti
Federico Moretti
FMFlavia Mallegni
Flavia Mallegni
RPRaffaele Palmieri
Raffaele Palmieri
LMLuca Maurillo
Luca Maurillo
In acute myeloid leukemia (AML) many patients experience relapse, despite the achievement of morphological complete remission; therefore, conventional morphologic criteria are currently considered inadequate for assessing the quality of the response after treatment. Quantification of measurable residual disease (MRD) has been established as a strong prognostic marker in AML and patients that test MRD negative have lower relapse rates and better survival than those who test positive. Different techniques, varying in their sensitivity and applicability to patients, are available for the measurement of MRD and their use as a guide for selecting the most optimal post-remission therapy is an area of active investigation. Although still controversial, MRD prognostic value promises to support drug development serving as a surrogate biomarker, potentially useful for accelerating the regulatory approval of new agents. In this review, we will critically examine the methods used to detect MRD and its potential role as a study endpoint.

Verified
Journal Article
Open access
PDF file
DCDaniela Cilloni
Daniela Cilloni
BMBeatrice Maffeo
Beatrice Maffeo
ASARIANNA SAVI
ARIANNA SAVI
ADAlice Costanza Danzero
Alice Costanza Danzero
Valentina BonuomoValentina Bonuomo
Valentina Bonuomo
CFCarmen Fava
Carmen Fava
More than 90% of patients affected by mastocytosis are characterized by a somatic point mutation of KIT, which induces ligand-independent activation of the receptor and downstream signal triggering, ultimately leading to mast cell accumulation and survival. The most frequent mutation is KIT p.D816V, but other rarer mutations can also be found. These mutations often have a very low variant allele frequency (VAF), well below the sensitivity of common next-generation sequencing (NGS) methods used in routine diagnostic panels. Highly sensitive methods are developing for detecting mutations. This review summarizes the current indications on the recommended methods and on how to manage and interpret molecular data for the diagnosis and follow-up of patients with mastocytosis.

23 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Elisa BuzzattiElisa Buzzatti
Elisa Buzzatti
FFFabio Forghieri
Fabio Forghieri
GPGiovangiacinto Paterno
Giovangiacinto Paterno
FMFrancesco Marchesi
Francesco Marchesi
CSChiara Sarlo
Chiara Sarlo
MPMaria Ilaria Del Principe
Maria Ilaria Del Principe
Hypofibrinogenemia (HF) in adult acute lymphoblastic leukemia (ALL) of B lineage is uncommon and mostly associated with asparaginase (ASP) delivery. Since we noticed a significant reduction in fibrinogen (FBG) plasma levels even before the first ASP dose, we aim to assess the levels of FBG during induction treatment and explore if the FBG fall correlated with therapies other than asparaginase and/or specific leukemia biological features. We retrospectively analyzed FBG levels in 115 patients with B-ALL. In 74 (64%) out of 115 patients FBG decline occurred during the steroid prephase. In univariate analysis, such a steroid-related HF was significantly associated with BCR-ABL1 rearrangement (p = 0.00158). None of those experiencing HF had significant modifications of liver function tests during induction treatment. Our retrospective study suggests that in B-ALL, steroid therapy can also induce HF and that such an event is preferentially observed in patients carrying BCR-ABL1 rearrangements. The pathogenesis of this phenomenon is still unclear. We attempt to explain it by applying the International Society of Thrombosis and Hemostasis-Disseminated Intravascular Coagulation score (ISTH-DIC score); nonetheless additional studies are needed to clarify further the mechanisms of HF in this subset of patients.

30 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
DCDaniela Cilloni
Daniela Cilloni
BMBeatrice Maffeo
Beatrice Maffeo
ASARIANNA SAVI
ARIANNA SAVI
ADAlice Costanza Danzero
Alice Costanza Danzero
Valentina BonuomoValentina Bonuomo
Valentina Bonuomo
CFCarmen Fava
Carmen Fava
More than 90% of patients affected by mastocytosis are characterized by a somatic point mutation of c-KIT, which induces ligand-independent activation of the receptor and downstream signal triggering, ultimately leading to mast cell proliferation and survival. The most frequent mutation is c-KIT p.D816V, but other rarer mutations can also be found. These mutations often have a very low variant allele frequency (VAF), well below the sensitivity of common next-generation sequencing (NGS) methods used in routine diagnostic panels. Highly sensitive methods are developing for detecting mutations. This review summarizes the current indications on the recommended methods and on how to manage and interpret molecular data for the diagnosis and follow-up of patients with mastocytosis.